Indeed, others have suggested a role for SETBP1 in the direct transcriptional activation of the HOXA9 and HOXA10 genes in both human and mouse myeloid progenitors 11 ( Fig. 1b) . Makishima et al. 4 verified this finding by showing that overexpression of either wild-type or mutant SETBP1 immortalized mouse myeloid progenitors and resulted in upregulation of Hoxa9 and Hoxa10. Notably, cells expressing mutant SETBP1 had higher proliferative capacity and greater ability to form colonies in vitro compared to controls expressing wild-type SETBP1. Additionally, the authors verified that this oncogenic phenotype was dependent on Hoxa9 and Hoxa10 expression, as ablation of either gene halted the ability of myeloid progenitors to form colonies in vitro.
Another possibility is that the mutations affecting the SKI-homologous domain may alter SETBP1 protein function by increasing its stability. Piazza et al. proposed that these mutations disrupt a phosphodegron that is a key signal for recognition by the E3 ubiquitin ligase βTRCP1, thereby allowing SETBP1 to avoid ubiquitination and subsequent proteasomal degradation 3 (Fig. 1b) . This mechanism supports the idea that mutant SETBP1 can evade post-translational control, thereby sustaining its oncogenic potential in a manner that could persist in the absence of transcriptional overexpression. However, Makishima et al. 4 report that mutant SETBP1 protein is no more stable than wild-type protein and that its mRNA transcript tends to be overexpressed in mutant cases as well as in a subset of cases with wild-type SETBP1.
Together, these three reports implicate SETBP1 as a new player in the pathogenesis of a wide spectrum of myeloid malignancies. Although SETBP1 mutational status has been suggested as a prognostic marker, its potential value as a target for therapeutic intervention will become clearer when the molecular functions of both the wild-type and mutant proteins are better understood. The consideration of SETBP1 as an oncogenic factor is especially interesting owing to its apparent functional duality as both a negative regulator of PP2A activity and a transcriptional regulator. Whereas regulation of the HOXA gene cluster by the SET-SETBP1 complex has previously been reported, Piazza et al. also demonstrated that many transforming growth factor (TGF)-β-responsive genes were upregulated in SETBP1-mutant cases. This interesting observation suggests that SETBP1 may have a direct role in the transcriptional regulation of other genes, a hypothesis worthy of further study. Continued investigation into the physiological activity of SETBP1 will be needed to gain a complete understanding of how each of its proposed functions can contribute to disease. Finally, the development of animal models using SETBP1 mutations combined with other lesions, such as mutations affecting ASXL1 and CBL, may allow for further insights into myeloid tumors.
MaPping the genomic landscape of low-grade pediatric gliomas
Sevin Turcan & Timothy A Chan
Two recent large-scale sequencing studies have identified multiple genetic aberrations in pediatric low-grade gliomas. These findings offer substantial insights that may spur the development of new diagnostics and treatments for these cancers. Large-scale sequencing efforts have facilitated the dawn of a new era in deciphering the molecular basis of pediatric brain tumors. Only a short time ago, these tumors were collectively considered a veritable 'black box' of ill-defined pathological entities. In the past year, new mutations in medulloblastoma [1] [2] [3] and driver mutations in histone H3.3 and chromatin-remodeling factor genes in pediatric glioblastoma 4, 5 have been identified, providing key insights for the development of novel treatments for affected patients. Low-grade gliomas (LGGs) commonly affect children and include World Health Organization (WHO) grade I pilocytic astrocytomas, grade II diffuse gliomas and other entities such as pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas. Whereas most pilocytic astrocytomas have a favorable prognosis,
LGGs that cannot be completely resected ultimately cause significant morbidity and mortality, despite their slow growth. Even though previous studies have linked LGGs to the abnormal activation of the mitogenactivated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) pathway 6 , little was known about the specific genetic alterations driving this pathway. Now, two independent genomic studies from David Ellison and colleagues 7 and Stefan Pfister and colleagues 8 provide the first clear overview of the genomic landscape of lower grade pediatric gliomas.
Many roads, one destination
Zhang et al. 7 report whole-genome, transcriptome and targeted high-throughput sequencing of pediatric lower grade tumors. Overall, few genetic alterations were identified, with a median of only a single alteration per tumor. In agreement with previous studies 9,10 , Zhang et al. 7 confirmed the presence of KIAA1549-BRAF fusions that lack the portion of BRAF encoding its regulatory domain, leading to constitutive BRAF activation, in 59% of pilocytic LGGs can have differing genomic alterations that ultimately converge so as to achieve activation of a few common signaling pathways (Fig. 1) .
It remains to be seen whether alterations in the epigenome contribute to pediatric LGGs. Both studies indicated that, unlike adult LGGs, in which hotspot mutations in IDH1 or IDH2 are found in more than 70% of tumors 11, 12 and tend to co-occur with TP53 and ATRX mutations or with 1p or 19q loss 13-15 , pediatric LGGs are mainly driven by genetic aberrations that activate kinase signaling. At least, from what we know so far, driver mutations in the epigenetic machinery seem to be reserved for higher grade pediatric glioblastomas 5 . Indeed, Jones et al. identified only one FGFR1-mutant tumor that also had a mutation affecting histone H3.3. These findings indicate a small degree of overlap between the genes that drive pediatric LGGs and those that drive higher grade gliomas. It remains to be seen whether such overlapping mutations can serve as prognostic factors for progression.
Are we there yet? The data described above significantly advance understanding of these once-enigmatic tumors. However, much work remains. In comparison to adult LGGs, malignant transformation is less frequent for pilocytic astrocytomas and certain other lower grade tumors in children. It is unclear whether this difference is due to the relatively stable nature of pediatric LGG cancer genomes, to differing cells of origin for these two cancers or to other unknown factors. If a pediatric LGG recurs, does it accumulate more mutations and remain distinct from its adult counterpart? Future studies are needed to shed light on these important questions.
The findings of Zhang et al. 7 and Jones et al. 8 converge on the hypothesis that, despite the mutational heterogeneity among different tumors, genetic alterations in LGGs commonly lead to the activation of the MAPK-ERK and PI3K pathways. This observation suggests the selective FGFR inhibitors blocked the autophosphorylation of TKD-duplicated FGFR1, thus providing a rationale for targeting FGFR1 or its downstream effectors in pediatric LGGs. In addition to duplications, missense mutations in FGFR1 and FGFR-TACC fusions were also identified that can activate the MAPK-ERK and PI3K pathways.
In an independent study, Jones et al. 8 sequenced 96 pilocytic astrocytomas and also noted an extremely low rate of mutation. They reported the presence of KIAA1549-BRAF fusion variants, along with four new BRAF fusions and a single three-amino-acid insertion in the interdomain cleft of BRAF, which increased ERK phosphorylation as effectively as the BRAF V600E mutation. Interestingly, in the 19% of non-cerebellar tumors that lacked an alteration in BRAF or KRAS, new NTRK2 gene fusions affecting its kinase domain were identified. The resulting chimeric tyrosine kinases probably mediate ligand-independent dimerization, leading to a dominantly acting astrocytomas and BRAF V600E mutations in 70% of PXAs. They further identified new rearrangements and amplifications of MYB in 25% of diffuse cerebral gliomas. Intriguingly, they found recurrent intragenic duplications of the region of FGFR1 encoding the tyrosine kinase domain (TKD) in 24% of diffuse grade II cerebral gliomas. In theory, these duplications would bring together two tyrosine kinase domains, obviating the need for receptor dimerization to activate signaling. When the investigators orthotopically transplanted Tp53-null astrocytes expressing TKD-duplicated FGFR1, all mice developed high-grade astrocytomas with complete penetrance. Within these tumors, two pathways downstream of fibroblast growth factor receptor (FGFR) activation, the MAPK-ERK and phosphoinositide 3-kinase (PI3K) pathways, were both aberrantly activated. Likewise, ectopic expression of TKD-duplicated FGFR1 in vitro resulted in FGFR1 autophosphorylation and activation of both MAPK-ERK and PI3K pathways. Notably, Transcription factor NTRK2 Figure 1 The majority of genetic alterations in pediatric LGGs activate the MAPK-ERK pathway. MAPK pathway components with alterations identified in the studies by Zhang et al. 7 and Jones et al. 8 are indicated with red stars. Several factors linked to histone modification were also found to have genetic abnormalities in a small subset of samples (dashed box). These findings offer insight into novel approaches to targeted therapeutics for pediatric LGGs.
npg existence of a degree of biological homogeneity, which opens the door to developing better treatment options. In the near future, we will need to assess the response of affected patients to agents that target these pathways and explore possible mechanisms of resistance should this occur. Ultimately, it is tantalizing to envision a treatment paradigm for pediatric gliomas similar to that for other cancer types driven primarily by distinct kinases, as with the kinase inhibitors used to target BCR-ABL in chronic myelogenous leukemia. In the event that novel, effective treatment options come to fruition, it would be clear that the studies described here provided the direction needed to allow affected patients to successfully navigate their disease and treatment.
in the literature. Further, both studies report the notion that the top four mutated genes are tumor suppressors located close to each other on chromosome 3p (Fig. 1) . Hence, one-copy loss of 3p simultaneously results in haploinsufficiency for four tumor suppressors, VHL, PBRM1, SETD2 and BAP1. Notably, mutations in either BAP1 and SETD2 seem to have adverse prognostic significance, negatively affecting survival and tumor recurrence 10, 11 , and are likely secondary events to VHL or PBRM1 loss 10, 12 .
Using the PARADIGM pathway algorithm, integrated analysis from TCGA 8 showed that the HIF1A-ARNT hub is activated by VHL mutations. Further, frequent chromosome arm-level losses on chromosome 14q, associated with loss of HIF1A, were detected and associated with more advanced disease, which is consistent with previous observations 13 . In another original finding, Sato et al. 7 describe novel mutations of TCEB1, which encodes Elongin C, a vital component of the VHL complex that ubiquitinates HIFs. Targeted deep sequencing of TCEB1 identified eight mutations (3.3%), which all occurred in the context of LOH of chromosome 8. TCEB1 mutations exclusively involved VHL-binding site residues Tyr79 (n = 7) or Ala100 (n = 1). Further, they occurred in the context of wildtype VHL, and tumors harboring TCEB1 mutations had increased HIF expression. Although not reported by TCGA 8 , analysis of TCEB1 in publically available data supports this finding, with four TCEB1 mutations observed, all involving Tyr79 and concomitant LOH. chromatin and/or histone modifiers and intriguingly map to the frequently lost 3p21 locus. In this issue of Nature Genetics 7 and in a recent issue of Nature 8 , two tour de force multiplatform studies have significantly expanded our understanding of the molecular landscape in ccRCC. Notably, the new reports suggest that additional pathogenic mechanisms are at play and corroborate the suspicion that ccRCC is a metabolic disease 9 , with the results potentially yielding novel therapeutic insights for the care of kidney cancer.
ccRCC is a disease of 3p loss Using highly integrative analyses, The Cancer Genome Atlas (TCGA) Research Network 8 and Seishi Ogawa and colleagues 7 report on independent, large collections of samples from individuals with ccRCC, analyzing over 400 and 240 cases, respectively, through wholegenome, whole-exome, transcriptome analyses as well as through the use of additional genome-wide analytic platforms. Together, they provide an astonishingly clear view of the spectrum of genetic alterations that occur in this malignancy. Foremost, the studies further solidify the concept that allelic loss of 3p is a fundamental component of ccRCC pathogenesis. Using SNP arrays, the two studies reported loss of heterozygosity (LOH) at 3p in over 90% of cases (Fig. 1) . Interestingly, Sato et al. 7 found that LOH at 3p occurred through either simple 3p loss (77.6%) or copy-neutral LOH (uniparental disomy; 22.4%). These different mechanisms might explain the variable rates of 3p loss cited Renal cell carcinoma (RCC) is the eighth leading cause of cancer-related death in the United States and accounts for nearly 300,000 cases worldwide. RCC consists of several histological subtypes with distinct molecular alterations and clinical outcomes. ccRCC, characterized by high lipid and glycogen content that gives rise to its name, represents the most common and aggressive malignant subtype. For decades, ccRCC was defined by biallelic loss of VHL, which is located on chromosome 3p25. This biallelic loss occurs through 3p loss 1 and concomitant VHL mutation 2 or promoter methylation 3 . The VHL protein is an E3 ubiquitin ligase that ubiquitinates and targets hypoxiainducible transcription factors (HIFs) for proteasome-mediated degradation. Thus, loss of VHL function leads to the stabilization and accumulation of HIFs that upregulate proangiogenic genes, most notably, VEGF (encoding vascular endothelial growth factor), thereby explaining the success of effective VEGFtargeted therapies in ccRCC.
Recent large-scale sequencing projects have identified driver genes in ccRCC beyond VHL [4] [5] [6] . These studies identified frequently mutated tumor suppressors, including PBRM1, BAP1 and SETD2, all of which function as a clear picture of renal cell carcinoma 
